Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
NEW YORK, Sept. 12, 2016 -- Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that it has entered into a definitive agreement for the acquisition of Dermasilk™ Brands, a commercially available over-the-counter beauty product portfolio encompassing fourteen different products. The products are currently sold at several large retailers including Rite-Aid, CVS, Wal-Mart and K-Mart.
As part of the transaction, all assets from Dermasilk Brands, Inc. will be transferred to Ember Therapeutics, Inc.
“This is our third acquisition this year. The addition of the Dermasilk™ brand of products to our product line will allow us to expand on our current relationship with major retailers and provide additional revenues to Ember. Dermasilk products have a large customer following and are developed using the highest cutting edge science,” said Joseph Hernandez, Executive Chairman of Ember Therapeutics, Inc. “The revenues generated by these products and Migralex™, our other commercially available product, will help further the development of our two Phase 3 ready clinical programs in osteoarthritis and regenerative medicine.”
Dermasilk™ products are currently available at Rite-Aid, CVS, Wal-Mart, K-Mart, local pharmacies, and online at jet.com and the product website www.dermasilkbrands.com. To learn more about Dermasilk™ please access www.dermasilkbrands.com.
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a diversified pharmaceutical company commercializing and developing targeted therapies for pain, osteoarthritis, kidney fibrosis and other regenerative medicines. In particular, Ember Therapeutics, Inc. has a commercial stage pain product and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com.
Contact: Betty Rose (investors) (646) 406-6243 [email protected]
